Please login to the form below
enzalutamide
This page shows the latest enzalutamide news and features for those working in and with pharma, biotech and healthcare.
EMA starts review of Xtandi in non-metastatic prostate cancer
Reported in February, the study showed that adding Xtandi (enzalutamide) to treatment with anti-androgen hormone therapy reduced the risk of disease spreading or death by 71% compared with hormone therapy
Latest news
-
J&J’s Erleada first US drug for non-metastatic prostate cancer
It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and Astellas and their Xtandi (enzalutamide) product, which has also been
-
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer
The filings are based on the just-released results of the PROSPER trial, which show that adding Xtandi (enzalutamide) to treatment with anti-androgen hormone therapy reduced the risk of disease
-
Astellas extends phase III programme for Rydapt rival gilteritinib
Gilteritinib is one of a clutch of new drugs Astellas is banking on to inject renewed growth into its revenues as prostate cancer blockbuster Xtandi (enzalutamide) starts to slow down, and
-
Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A
The US's largest drugmaker booked $141m from Xtandi (enzalutamide) in the second quarter, up from $131m in the first quarter of the year and flat on the last quarter of
-
Pfizer hits accelerator on Xtandi trial in early prostate cancer
Originally due to report in mid-2019, the large-scale PROSPER trial of Xtandi (enzalutamide) in patients with non-metastatic, castration-resistant prostate cancer will now generate top-line results later
More from news
Approximately 13 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Cost containment and the German market
The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.
-
Deal Watch May 2016
The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
-
Astellas: Ten years young
Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Dendreon appoints new R&D lead
Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
-
Astellas promotes John Demaree
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
-
Astellas poaches new oncology head from Takeda
She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Account Manager – Med Comms – London
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Programme Executive
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Senior Medical Writer
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Medical Writer
-
Great salary and benefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior Account Manager / Account Director
-
Great salary and bebefits
Subscribe to our email news alerts
PMHub
Grace Communications
Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
